Evidence map›Paper›PMID 37092466›Full record

ArticleVision (Basel, Switzerland)2023

The Most-Cited Articles on Retinoblastoma: A Fifty-Year Perspective.

Rachel Shemesh, Hunter Sandler, Sarah Dichter, Ido Didi Fabian, Eedy Mezer, Tamara Wygnanski-Jaffe

Abstract read
In one paragraph

Article in Vision (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rachel ShemeshSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.ORCID 0000-0001-9572-4623
Hunter SandlerSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
Sarah DichterRuth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Ido Didi FabianSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.ORCID 0000-0002-0846-5131
Eedy MezerRuth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.ORCID 0000-0002-2818-7538
Tamara Wygnanski-JaffeSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo summarize the characteristics and trends of interest in retinoblastoma (Rb) in the last 50 years.

methodsThe Web of Science Database was used to find all studies focused on Rb published from 1970 to 2018. The term "retinoblastoma" was used to search for the 100 most cited records.

resultsThe mean number of citations was 153.55 ± 88.9. The majority were from the United States (US) (

conclusionsThis study compiles a comprehensive analysis of the most-cited articles on Rb. Studies with a higher number of citations per year were associated with IAC, which emphasizes the significance of the advances in Rb treatments that allow for the saving of eyes and vision as well as lives. Review studies had more citations than observational or interventional studies. More citations were associated with a larger number of authors or more reported patients per paper. These findings highlight the importance of collaborations to achieve relevant, high-quality research of Rb.

Indexed as

bibliometricschemotherapycitationsretinoblastomatreatment

Identifiers

PMID37092466
PMCPMC10123740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.